Published an article “Diagnostic efficacy of the new prospective biomarker’s combination CA 15-3 and CA-62 for early-stage breast cancer detection: Results of the blind prospective-retrospective clinical study”, Cancer Biomarkers, vol. Pre-press, no. Pre-press, pp. 1-13, 2022 showing the evaluation of the diagnostic efficacy of CA 15-3 and CA-62 cancer markers combination for early stages of breast cancer (BC) detection. Combination of different cancer markers is often used for predicting tumor growth, for the response to cancer therapy, and for increase in the positive diagnosis ratio in the malignant tumors.
A study included 300 BC patients (254 at Stages I and II, 20 with ductal carcinoma in situ (DCIS), and 26 Stages III and IV patients), 47 patients with breast benign diseases, and 141 healthy controls.
The results obtained in a blind study demonstrate that a combination of CA15-3 with CA-62 yields 75% Sensitivity at 100% Specificity for DCIS and Stage I breast cancer detection, which has a potential to be integrated into existing screening programs.
Contact
Viatcheslav Kondratiev, CEO
Universal Cancer Technologies (UCT)
800 Petrolia Road, Unit 3
Toronto, ON M3J 3K4 Canada
Phone: 416-661-7890
Email: [email protected]
About UCT
UCT is an emerging biotechnology company that has developed a sensitive cancer test that can reliably measure the amount of N-glycoprotein CA-62 biomarker in a routine blood draw. The test can detect the majority of epithelial cancer types at all stages of the disease (Stage I through Stage IV), even before a patient may become symptomatic. Because of its non-invasive approach and rapid turnaround time UCT’s CA-62 biomarker test is ideal for screening as well as for monitoring the success of ongoing cancer treatments and identifying relapses in remission patients.